'Trials For Nasal Covid Vaccine Slated For November'
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1548839_1_20200910182024.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1548839-20200910.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1548839-20200910.htm', 'DCS.dcsqry', '' ); } } }); }); });
2020-09-10 HKT 11:42
Hong Kong University microbiologist Professor Yuen Kwok-yung said they hope to start clinical trials for a new nasal spray vaccine for Covid-19 in November.
Yuen, who is the chair of infectious diseases at the university's department of microbiology, made the comments after HKU announced that mainland authorities had given the go ahead for clinical trials for the nasal spray – which it has been developing with some mainland institutions.
Speaking on a Commercial Radio programme, Yuen said that the university has received funding of about HK$20 million from the authorities, and they hope to recruit about 100 healthy people in Hong Kong for the trials.
He said that vaccine development requires three phases of clinical trials, and after the launch of phase one this year, it will take about one more year at the earliest before the vaccine can be used.
HKU's State Key Laboratory of Emerging Infectious Diseases has been working on the vaccine with Xiamen University and Beijing Wantai Biological Pharmacy.
Yuen said that since Hong Kong does not have its own facilities for developing vaccines, it needs to cooperate with the mainland.
HKU said their vaccine is so far the only nasal spray vaccine against the coronavirus to be approved by the National Medical Products Administration for clinical trials.
Ant Internationals Ant Bank And Bettr Selected For Hong Kongs GenAI Sandbox++
Digital bank Ant Bank and embedded financial solutions provider Bettr have been selected to participate in Hong Kong’... Read more
Visa And BOCHK Tapped For Hong Kong AI Sandbox To Test Agent-Initiated Commerce
Visa has announced that it is partnering with Bank of China (Hong Kong) (BOCHK) in the GenA.I. Sandbox++. With the Visa... Read more
Hong Kong Regulators Pick 36 Agentic AI Use Cases For GenA.I. Sandbox++
The Hong Kong Monetary Authority (HKMA), the Securities and Futures Commission (SFC), the Insurance Authority (IA), and... Read more
Finloop And Yunfeng Financial Become Latest Anchorpoint Authorised Distributors
Finloop and Yunfeng Financial have joined Anchorpoint’s HKDAP stablecoin beta access programme as authorised distribu... Read more
Standard Chartered Becomes First Bank To Distribute HKDAP Stablecoin
Standard Chartered Bank (Hong Kong) Limited (SCBHK) has become the first bank distributor of HKDAP, the Hong Kong dolla... Read more
Lianlian DigiTech Profit Doubles In H12026, Agent Wallet Pushes To Address Payment Needs
Lianlian DigiTech Co., Ltd, a payment service provider headquartered in China, reported its interim results for the fir... Read more
